促性腺激素释放激素激动剂治疗子宫腺肌病合并不孕

目的探讨促性腺激素释放激素激动剂(GnRH-a)对子宫腺肌症合并不孕的疗效.方法对12例子宫腺肌症合并不孕者行GnRH-a治疗,同时加用甾体激素"反加疗法”,部分病例应用辅助生殖技术.治疗前后用B超、核磁共振(MRI)、血清CA125和生殖激素(FSH、LH、E2)及骨密度(BMD)测定.结果治疗后痛经等症状缓解,B超和MRI提示子宫腺肌病病灶基本消退,子宫大小83.33%(10/12)恢复正常,血CA125、FSH、LH、E2水平显著降低(P＜0.01),腰椎BMD无明显变化(P＞0.05),妊娠率达75.0%.结论GnRH-a是治疗子宫腺肌病合并不孕的一种有效方法.     

促性腺激素素释放激素激动剂治疗子宫腺肌病合并不孕

目的：探讨促性腺激素素释放激素激动剂（GnRH-a)对子宫腺肌症合并不孕的方法。方法：对12例子宫腺肌症合并不孕者行GnRH-a治疗,同时加用甾体激素“反加疗法”,部分病例应用辅助生殖技术,治疗前后用B超、核磁共振（MRI）、血清CA125和生殖激素（FSH、LH、E2）及骨密度（BMD）测定。结果：治疗后痛经症状缓解,B超和MRI提示子宫肌腺病病灶基本消退,子宫大小83．33％（10／12）恢复正常,血CA125、FSH、LH、E2水平显著降低（P＜0．01）,腰椎BMD无明显变化（P＞0．05）,妊娠率达75．0％。结论GnRH-a是治疗子宫腺肌病合并不孕的一种有效方法。     

子宫腺肌病合并不孕患者的生殖预后及助孕策略

在子宫结构异常疾病中,子宫腺肌病在育龄妇女中有较高的发病率。随着影像技术和治疗水平的提高,越来越多的研究表明子宫腺肌病可能影响育龄妇女的生育能力。子宫腺肌病合并不孕的机制尚不明确,子宫内膜容受性异常、子宫结合带的结构异常、免疫功能异常等可能是子宫腺肌病患者生育能力低下的原因。希望保留生育能力的主要治疗方案有药物治疗、辅助生殖技术(ART)和手术切除子宫腺肌病灶。目前,ART可以改善子宫腺肌病合并不孕症患者的妊娠结局,促性腺激素释放激素类似物对生殖有积极的影响,在子宫腺肌病合并不孕症应用中有很重要的价值。综述子宫腺肌病合并不孕症影响生育的可能机制、生殖结局及治疗策略以探讨子宫腺肌病与不孕的关系。     

糖皮质激素联合GnRH-α在轻度子宫内膜异位症合并复发性早期流产患者中的疗效评价

目的探讨糖皮质激素联合促性腺激素释放激素激动剂(GnRH-α)在降低轻度子宫内膜异位症(EMT)患者复发性早期流产中的疗效。方法选择2016年5月至2017年3月本院收治的77例轻度EMT合并复发性流产患者纳入研究,根据患者意愿腹腔镜术后分别给予单纯GnRH-α治疗(GnRH-α组,n=37)和GnRH-α联合糖皮质激素治疗(联合组,n=40)。测定患者血清C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E_2)和孕酮水平;进行视觉模拟评分法(VAS)疼痛评分,随访疼痛缓解、复发及受孕情况。结果联合组术后第1、3天各炎症因子水平低于GnRH-α组(P0.05),E_2、孕酮水平显著高于GnRH-α组(P0.05);联合组患者术后第6、12个月疼痛VAS评分明显低于GnRH-α组(P0.05);联合组患者术后疼痛和EM病灶复发率显著低于GnRH-α组(P0.05),活产率(60.00%,24/40)显著高于GnRH-α组(35.14%,12/37)(P0.05);两组患者的不良反应发生率比较,差异无统计学意义(P0.05)。结论 GnRH-α联合糖皮质激素对于缓解EMT合并复发性自然流产患者腹腔镜术后疼痛、降低术后复发、提高妊娠结局方面均有一定效果。     

腹腔镜下子宫腺肌瘤局灶切除术联合GnRH-a治疗的效果研究

目的:比较腹腔镜下子宫腺肌瘤局灶切除术与术后联合促性腺激素释放激素激动剂(GnRH-a)在子宫腺肌瘤合并不孕症患者治疗中的效果。方法:根据治疗方法的不同将研究对象分为两组:行腹腔镜下子宫腺肌瘤局灶切除术联合GnRH-a治疗者为研究组(72例),仅行腹腔镜下局灶切除术为对照组(70例)。分别于术后6个月、12个月、24个月进行电话随访,比较两组患者妊娠率、痛经症状缓解及子宫腺肌病复发情况。结果:研究组术后24个月累计妊娠率(27.78%)高于对照组(12.86%),差异有统计学意义(P0.05)。研究组和对照组患者术后痛经缓解有效率分别为86.11%、81.43%,差异无统计学意义(P0.05)。2年随访期间研究组复发率(8.33%)低于对照组(18.57%),差异有统计学意义(P0.05)。结论:腹腔镜下局灶切除术后联合GnRH-a药物治疗可以改善子宫腺肌病患者的痛经症状,与单纯行腹腔镜下局灶切除术相比,联合治疗的妊娠率更高,短期内降低复发。     

子宫腺肌病合并不孕患者的生殖预后及助孕策略

在子宫结构异常疾病中，子宫腺肌病在育龄妇女中有较高的发病率。随着影像技术和治疗水平的提高，越来越多的研究表明子宫腺肌病可能影响育龄妇女的生育能力。子宫腺肌病合并不孕的机制尚不明确，子宫内膜容受性异常、子宫结合带的结构异常、免疫功能异常等可能是子宫腺肌病患者生育能力低下的原因。希望保留生育能力的主要治疗方案有药物治疗、辅助生殖技术（ART）和手术切除子宫腺肌病灶。目前，ART可以改善子宫腺肌病合并不孕症患者的妊娠结局，促性腺激素释放激素类似物对生殖有积极的影响，在子宫腺肌病合并不孕症应用中有很重要的价值。综述子宫腺肌病合并不孕症影响生育的可能机制、生殖结局及治疗策略以探讨子宫腺肌病与不孕的关系。     

病灶切除术联合药物治疗子宫腺肌病89例临床分析

目的:比较单纯子宫腺肌病病灶切除术与病灶切除术后联合促性腺激素释放激素激动剂(GnRH-α,亮丙瑞林注射液)或口服避孕药(去氧孕烯-炔雌醇,妈富隆片)治疗子宫腺肌病的疗效。方法:收集2006年7月至2009年7月在我院行子宫腺肌病病灶切除手术89例患者的临床资料,并对其进行随访,分析手术加GnRH-α、手术加妈富隆及单纯手术3种治疗方法的疗效。结果:3组患者治疗后痛经评分及月经量都较治疗前下降,月经量下降例数百分比分别为82.1%、83.3%和55.8%。手术加GnRH-α组治疗后痛经评分明显低于手术加妈富隆组(0.93±1.30VS2.00±1.88,P=0.027),且其痛经缓解和消失比例明显高于另两组(P=0.023;P=0.019)。3组患者随访期间复发率分别为14.3%、22.2%和39.5%。复发者与无复发者相比,年龄、初潮年龄、产次、瘤体大小、瘤体位置、手术方式及治疗前月经情况比较,差异均无统计学意义(P>0.05),但腺肌瘤病灶多发患者复发率显著高于单发患者(P=0.003),且绝大部分复发患者在治疗前有痛经。结论:病灶切除手术后无论是否辅助药物治疗均能有效治疗子宫腺肌病,术后辅助GnRH-α...     

子宫腺肌病保留生育功能手术治疗进展

子宫腺肌病是一种严重危害女性生育功能的疾病,目前保留生育功能的治疗以促性腺激素释放激素激动剂(GnRH-a)为代表的药物结合辅助生殖为主。近年来,手术在重建子宫腺肌病生育功能的治疗中取得了长足的进展,子宫腺肌病病灶切除术在子宫腺肌病不孕症的治疗中起到不可替代的作用,对于39岁患者存在胚胎反复种植失败史、后壁局灶性腺肌病灶引起宫腔形态改变者,部分患者在保留生育功能的病灶切除术后可获得成功妊娠。高强度聚焦超声无创性消融子宫腺肌病灶是值得进一步临床研究的、有前景的保留生育功能的治疗方法。鉴于子宫动脉栓塞术对卵巢功能及子宫内膜的影响,在有生育要求的症状性子宫腺肌病中应慎用。     

子宫腺肌病腹腔镜病灶切除术后应用促性腺激素释放激素激动剂联合中药内异消临床研究

目的探讨腹腔镜病灶切除术后应用促性腺激素释放激素激动剂(GnRH-a)联合中药内异消治疗子宫腺肌病并保留生育功能的可行性。方法收集2014年10月至2016年10月在上海中医药大学附属曙光医院妇科住院治疗的生育期子宫腺肌病患者32例,应用悬吊式腹腔镜联合改良环形电切术进行子宫腺肌病病灶切除术,术后均给予注射Gn RH-a治疗6个月及中药内异消口服12个月。术后随访18个月,比较治疗前后月经量、痛经、子宫体积、血清CA125变化情况和中医证候积分以及复发率和妊娠率。结果与治疗前比较,Gn RH-a治疗后首次月经来潮时及术后12、18个月的月经量、痛经和中医证候积分差异有统计学意义(P0.05),子宫体积和血清CA125均显著下降(P0.05)。手术后18个月复发率3.13%,妊娠率6.25%。内异消服用12个月后,患者肝肾功能均正常。结论子宫腺肌病腹腔镜病灶切除术后应用GnRH-a联合中药内异消治疗可显著改善月经过多、痛经等症状,复发率降低,部分患者仍可妊娠分娩。内异消长期服用无明显影响肝肾功能等副反应。     

LNG-IUD治疗围绝经后期子宫腺肌病92例临床分析

目的:通过宫腔内放置左炔诺酮宫内节育器(LNG-IUD)治疗围绝经后期子宫腺肌病患者的随访观察,评价其治疗效果.方法:对92例围绝经后期子宫腺肌病并放置LNC-IUD的患者进行3、6、12、24个月随访,观察月经变化、子宫体积、痛经程度、血清CA_(125)水平.结果:本组92例子宫腺肌病患者置入LNG-IUD后,随着随访时间延长痛经明显缓解(P<0.05);月经减少,子宫体积及血清CA_(125)水平明显下降(P<0.05).结论:LNG-IUD治疗囤绝经后期子宫腺肌病患者操作简便,疗效可靠.     

Live birth after conservative surgery for severe adenomyosis following magnetic resonance imaging and gonadotropin-releasing hormone agonist therapy

This is a report of a live birth after conservative surgery for severe adenomyosis following diagnosis by MRI and therapy with GnRH-a. A 33-year-old gravida 1 para 1 woman with a 5-year history of secondary infertility received a gonadotropin-releasing hormone agonist (GnRH-a), leuprolide acetate, for 16 weeks to control symptoms of severe adenomyosis and to treat infertility. However, severe dysmenorrhea recurred after the discontinuation of therapy. Because an elevated serum level of CA-125 and MRI findings suggested that she was experiencing a relapse of adenomyosis, GnRH-a therapy was re-instituted. After 24 weeks of the second therapy, her uterus decreased to normal size and an MRI revealed a localized low-signal-intensity myometrial mass with well-defined borders. We easily resected the localized lesion of adenomyosis using the same technique used to treat uterine leiomyoma. The patient became pregnant after 12 weeks of additional danazol therapy. A healthy male infant was delivered at term by cesarean section.     

Fertility outcome of infertile women with adenomyosis treated with the combination of a conservative microsurgical technique and GnRH agonist: long-term follow-up in a series of nine patients

ObjectiveThis paper reports the long-term follow-up (62–83 months) of women with unexplained subfertility secondary to severe adenomyosis treated with the combination of conservative surgery and gonadotropin releasing hormone agonist (GnRH agonist) therapy.Materials and MethodsA retrospective study included nine patients with a history of > 3 years of unexplained infertility who had extensive uterine adenomyosis. These nine couples were diagnosed with unexplained infertility after excluding other possible causes, such as the male factor, ovulation disorders, structural abnormality, and infections. All were essentially normal except for presumed uterine adenomyosis and elevated serum levels of CA125. All underwent a careful excision of the adenomyosis tissue using a microsurgical technique, and then a six-month course of GnRH agonist therapy. The outcome evaluations included serum level of CA125, degree of dysmenorrhea, and rate of spontaneous pregnancy.ResultsPostoperative follow-up showed that the severity of dysmenorrhea was significantly improved. The improvement scale was positively correlated with a decline in the serum level of CA125. A postoperative serum CA125 decreased to less than 10.00 IU/mL predicted well the spontaneous pregnancy rate, especially during the therapy. In the end, only two women became pregnant and finally delivered viable babies in this study.ConclusionsAlthough the combination of careful conservative surgery and GnRH agonist therapy might provide some benefits in patients with unexplained infertility and presumed severe adenomyosis, two-thirds of the patients still failed to become pregnant. The postoperative serum level of CA125 could predict the future pregnancy rate.     

子宫腺肌病的助孕策略

随着影像技术的发展,子宫腺肌病与不孕的相关性日益受到重视,辅助生殖技术是子宫腺肌病相关不孕患者的首选治疗,其促排方案和辅助生殖技术策略有别于其他患者。文章就子宫腺肌病患者的助孕策略进行阐述。     

GnRH-a联合炔诺酮治疗子宫腺肌病的疗效与安全性研究

目的 :探讨促性腺激素释放激素激动剂 (GnRH a)与炔诺酮联合治疗子宫腺肌病的疗效及安全性。方法 :将 6 0例子宫腺肌病患者随机分为两组 ,每组 30例。A组采用GnRH a加炔诺酮治疗 ;B组单独应用GnRH a。观察治疗前后症状、体征、肝肾功能、血脂代谢、腰椎骨密度 (BMD)变化 ,统计停药后妊娠率。结果 :两组总主观症状评分及子宫体积于治疗后均明显下降 ,两组治疗后肝肾功能、空腹血糖均在正常范围。血甘油三脂 (TG)、载脂蛋白A(ApoA)、血钙、磷、碱性磷酸酶、BMDB组治疗后与治疗前比较及两组间比较差异均有显著性 ,A组发生低雌激素症状较B组明显少。A、B组治疗后妊娠率分别为 4 6 7%、4 1 4 % (P <0 0 5 )。结论 :GnRH a联合炔诺酮可有效治疗子宫腺肌病 ,提高妊娠率 ,并能减轻低雌激素症状 ,降低出血率 ,减缓骨转换。     

Effects of short-course buserelin therapy on adenomyosis. A report of two cases.

BACKGROUND: Hysterectomy and hysteroscopic endometrial ablation remain common treatment of symptomatic adenomyosis for women who have completed childbearing. However, for patients who wish to avoid surgery and in whom adenomyosis is suspected of causing infertility, repeated abortion or physical symptoms, medical treatment with gonadotropin-releasing hormone analogue (GnRH-a) should be considered. CASES: Two cases of documented adenomyosis were suspected of causing infertility; both were treated with a three-month course of GnRH-a via a nasal spray. Both patients experienced relief of symptoms and conceived within six months of the cessation of treatment. CONCLUSION: The efficacy and safety of a short course of GnRH-a treatment of adenomyosis may be considered in patients who take less time than others to achieve a significant reduction of uterine size and relief of symptoms and in those who develop side effects.     

血清及腹腔液CA125测定对子宫腺肌病的诊断价值

目的探讨血清及腹腔液CA125测定对子宫腺肌病的诊断价值.方法采用免疫化学发光法测定28例子宫腺肌病和25例子宫肌瘤患者血清及腹腔液(110稀释)CA125水平.结果子宫腺肌病患者血清CA125水平高于子宫肌瘤患者,差异有显著性(P＜0.01).两组间腹腔液CA125水平差异无显著性(P=0.18).腹腔液CA125水平明显高于血清CA125水平(P＜0.01),但二者无明显相关性(P＞0.50).腺肌病患者血清CA125水平受子宫大小、大体病理类型、使用性激素等因素影响.结论如用于子宫腺肌病的辅助诊断,血清CA125测定较腹腔液CA125测定敏感.腹腔液中CA125的主要来源可能为腹膜上皮细胞.     

黑升麻在中重度子宫内膜异位症GnRH-a反加治疗中的疗效评估

目的:比较黑升麻和替勃龙在中重度子宫内膜异位症腹腔镜术后GnRH-a反加治疗中的疗效。方法:前瞻性随机对照比较中重度子宫内膜异位症腹腔镜术后患者90例,分为戈舍瑞林+黑升麻组、戈舍瑞林+替勃龙组、戈舍瑞林组,各30例,分析各组用药3个月后血清雌二醇(E2)、促卵泡激素(FSH)水平;子宫内膜厚度;Kupperman(KMI)评分;视觉疼痛症状评分法(VAS)评分;血清骨钙素(BGP);CA125、肝肾功能、血脂等变化。结果:戈舍瑞林+替勃龙组血清E2水平显著高于戈舍瑞林+黑升麻组及戈舍瑞林组(P均<0.05),FSH显著低于戈舍瑞林+黑升麻组及戈舍瑞林组(P均<0.05),戈舍瑞林+黑升麻组和戈舍瑞林组间无差异(P>0.05);戈舍瑞林组KMI评分明显高于戈舍瑞林+替勃龙组和戈舍瑞林+黑升麻组(P<0.05),而戈舍瑞林+替勃龙组和戈舍瑞林+黑升麻组间无差异(P>0.05);戈舍瑞林+替勃龙组血清BGP浓度显著低于戈舍瑞林组和戈舍瑞林+黑升麻组(P均<0.05),而戈舍瑞林组和戈舍瑞林+黑升麻组间无差异(P>0.05)。各组间EM、VAS评分、CA125、肝肾功能及血脂等均无明显差异(P>0.05)。结论:黑升麻是中重度子宫内膜异位症腹腔镜术后GnRH-a反加治疗安全有效的选择之一。     

Increased natural killer cell activities in patients treated with gonadotropin releasing hormone agonist.

Natural killer (NK) cell activity in patients treated with gonadotropin-releasing hormone agonists (GnRH-a) was studied. The subjects were 8 patients with endometriosis (6 with ovarian endometrial cyst, 2 with adenomyosis) and 3 patients with uterine leiomyoma. Changes in serum estradiol (E2) concentration and NK cell activity in peripheral blood were analyzed before and after GnRH-a treatment (buserelin 900 microg/day for 4-5 months). NK cell activity was determined by 51Cr release assay and E2 by radioimmunoassay. NK cell activity before GnRH-a treatment was 37.7 +/- 19.0%, and after therapy activity increased significantly to 50. 8 +/- 18.2%. However, no significant correlation between the increase in NK cell activity and the decrease in E2 concentration was found. Results indicate that the standard GnRH-a treatment for endometriosis and uterine leiomyoma might increase NK cell activity. The etiology of the increase of NK activity with GnRH-a treatment is likely related to factors other than E2 concentration.     

GnRH-a治疗腹腔镜术后子宫内膜异位症合并不孕症的作用机制与疗效

子宫内膜异位症(EMs)是育龄期女性的常见病,其中高达40%的患者合并不孕症。促性腺激素释放激素激动剂(GnRH-a)联合腹腔镜手术已成为治疗EMs相关不孕症的重要治疗措施,其通过改善盆腹腔微环境、提高子宫内膜容受性、提高卵泡及胚胎质量等多方面改善EMs患者的生育能力,对提高腹腔镜术后EMs患者的自然妊娠与辅助妊娠结局具有一定的价值。